HSCS · HeartSciences Inc. · Executive Compensation
$3.13
+0.06 (+1.95%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Sep 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Sep 14, 2026
Market Cap
$15.02M
Shares
4.80M
Volume · Oct 20
42.82K
Avg daily vol (3M)
157.96K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Erik Ellingson | Chief Financial Officer | Appointed | 2026-06-23 |
| Andrea Childs | Chief Executive Officer | Appointed | 2026-06-23 |
| David R. Wells | Board of Directors | Appointed | 2023-03-16 |
| David R. Wells | director | Appointed | 2023-01-03 |
| Patrick Kanouff | member of the Board of Directors | Resigned | 2023-01-03 |
Leadership
- Andrea Childs CEO, Board Member
- Erik Ellingson CFO
- David R. Wells Board Member